{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05156710",
            "orgStudyIdInfo": {
                "id": "ACT17012"
            },
            "secondaryIdInfos": [
                {
                    "id": "U1111-1267-2612",
                    "type": "REGISTRY",
                    "domain": "ICTRP"
                },
                {
                    "id": "2023-509936-25-00",
                    "type": "REGISTRY",
                    "domain": "CTIS"
                },
                {
                    "id": "2023-509936-25",
                    "type": "REGISTRY",
                    "domain": "CTIS"
                },
                {
                    "id": "2021-000010-41",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Sanofi",
                "class": "INDUSTRY"
            },
            "briefTitle": "BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)",
            "officialTitle": "A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.",
            "therapeuticArea": [
                "Other"
            ],
            "study": "n-prevention-and-treatment-of-antibody-mediated-rejection-amr"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-06-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-14",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-11-18",
            "studyFirstSubmitQcDate": "2021-12-13",
            "studyFirstPostDateStruct": {
                "date": "2021-12-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sanofi",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Primary Objectives:\n\n* Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR\n* Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR\n\nSecondary Objectives:\n\n* To assess the overall efficacy of BIVV020 in prevention or treatment of AMR\n* To characterize the safety and tolerability of BIVV020 in kidney transplant participants\n* To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants\n* To evaluate the immunogenicity of BIVV020",
            "detailedDescription": "Up to approximately 2 years"
        },
        "conditionsModule": {
            "conditions": [
                "Transplant Rejection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "Randomization for Cohort B only"
                }
            },
            "enrollmentInfo": {
                "count": 45,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "BIVV020 with Standard of Care (SOC) Cohort A",
                    "type": "EXPERIMENTAL",
                    "description": "Eligible participants will receive BIVV020 and SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.",
                    "interventionNames": [
                        "Drug: BIVV020 (SAR445088)",
                        "Drug: Antithymocyte globulin (ATG)",
                        "Drug: Tacrolimus",
                        "Drug: Mycophenolate"
                    ]
                },
                {
                    "label": "BIVV020 with Standard of Care (SOC) Cohort B",
                    "type": "EXPERIMENTAL",
                    "description": "Eligible participants will receive BIVV020 and SOC which includes plasmapheresis, IVIg, corticosteroids, rituximab.",
                    "interventionNames": [
                        "Drug: BIVV020 (SAR445088)",
                        "Drug: Intravenous immunoglobulin (IVIg)",
                        "Drug: Rituximab or biosimilar",
                        "Drug: Corticosteroids"
                    ]
                },
                {
                    "label": "Standard of Care (SOC) Cohort B",
                    "type": "OTHER",
                    "description": "SOC includes plasmapheresis, IVIg, corticosteroids, rituximab.",
                    "interventionNames": [
                        "Drug: Intravenous immunoglobulin (IVIg)",
                        "Drug: Rituximab or biosimilar",
                        "Drug: Corticosteroids"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BIVV020 (SAR445088)",
                    "description": "Pharmaceutical Form: Solution for injection Route of Administration: Intravenous",
                    "armGroupLabels": [
                        "BIVV020 with Standard of Care (SOC) Cohort A",
                        "BIVV020 with Standard of Care (SOC) Cohort B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Intravenous immunoglobulin (IVIg)",
                    "description": "Pharmaceutical Form: Solution for injection Route of Administration: Intravenous",
                    "armGroupLabels": [
                        "BIVV020 with Standard of Care (SOC) Cohort B",
                        "Standard of Care (SOC) Cohort B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Rituximab or biosimilar",
                    "description": "Pharmaceutical Form: Solution for injection Route of Administration: Intravenous",
                    "armGroupLabels": [
                        "BIVV020 with Standard of Care (SOC) Cohort B",
                        "Standard of Care (SOC) Cohort B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Antithymocyte globulin (ATG)",
                    "description": "Pharmaceutical Form: Solution for injection Route of Administration: Intravenous",
                    "armGroupLabels": [
                        "BIVV020 with Standard of Care (SOC) Cohort A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tacrolimus",
                    "description": "Pharmaceutical Form: Tablet Route of Administration: Oral",
                    "armGroupLabels": [
                        "BIVV020 with Standard of Care (SOC) Cohort A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Mycophenolate",
                    "description": "Pharmaceutical Form: Tablet Route of Administration: Oral",
                    "armGroupLabels": [
                        "BIVV020 with Standard of Care (SOC) Cohort A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Corticosteroids",
                    "description": "Pharmaceutical Form: Vary Route of Administration: Vary",
                    "armGroupLabels": [
                        "BIVV020 with Standard of Care (SOC) Cohort B",
                        "Standard of Care (SOC) Cohort B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Cohort A: Treatment failure rate",
                    "description": "Defined as the proportion of participants meeting at least one of the following criteria:\n\n* Biopsy-proven active AMR as per Banff Criteria 2019 as per central pathology assessment,\n* Graft loss.",
                    "timeFrame": "Up to Week 49"
                },
                {
                    "measure": "Cohort B: AMR resolution rate",
                    "description": "Defined as the proportion of participants with post-treatment biopsy not fulfilling active AMR diagnosis criteria as per Banff Criteria 2019 as per central pathology assessment.",
                    "timeFrame": "Up to Week 49"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Cohort A: Treatment failure rate per local assessment using Banff criteria 2019",
                    "timeFrame": "Up to Week 49"
                },
                {
                    "measure": "Cohort B: AMR resolution rate per local assessment using Banff criteria 2019",
                    "timeFrame": "Up to Week 49"
                },
                {
                    "measure": "Change in renal function from baseline per central laboratory assessment of estimated glomerular filtration rate (eGFR) from serum creatinine using Modification of Diet in Renal Disease equation (MDRD)",
                    "timeFrame": "Up to 22 weeks after end of treatment period"
                },
                {
                    "measure": "Change in renal function from baseline per central laboratory assessment using protein: creatinine ratio",
                    "timeFrame": "Up to 22 weeks after end of treatment period"
                },
                {
                    "measure": "Change in allograft histopathology Banff score",
                    "timeFrame": "Up to Week 49"
                },
                {
                    "measure": "Graft survival as predicted by iBOX",
                    "timeFrame": "Up to Week 49"
                },
                {
                    "measure": "Assessment of adverse events (AEs)",
                    "description": "Number of participants with treatment emergent adverse events (TEAEs)/ serious adverse events (SAES), laboratory abnormalities",
                    "timeFrame": "Up to end of study, up to approximately 2 years"
                },
                {
                    "measure": "Change in systemic lupus erythematosus (SLE) panel",
                    "timeFrame": "Up to 22 weeks after end of treatment period"
                },
                {
                    "measure": "Plasma exposure of BIVV020 assessing pharmacokinetic parameter Cmin",
                    "description": "Cmin is defined as the minimum concentration after injection",
                    "timeFrame": "Up to 22 weeks after end of treatment period"
                },
                {
                    "measure": "Plasma exposure of BIVV020 assessing pharmacokinetic parameter AUC",
                    "description": "AUC is defined as the area under plasma concentration versus time curve",
                    "timeFrame": "Up to 22 weeks after end of treatment period"
                },
                {
                    "measure": "Number of participants with anti-BIVV020 antibodies",
                    "description": "Number of participants developed drug-induced ADAs",
                    "timeFrame": "Up to 22 weeks after end of treatment period"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n-Participant intended to receive SOC therapy per Investigator's judgment and local practice.\n\nCohort A: Participants with chronic kidney disease who will receive a kidney transplant from a living or deceased donor.\n\nCohort B: Participants who are kidney transplant recipients diagnosed with active AMR.\n\n* BMI \u2264 40 kg/m2.\n* Contraceptive use by women during the treatment period, and for at least 49 weeks after the last administration of IMP (BIVV020 + SOC arm participant) or last treatment period visit (SOC arm participant).\n* Contraceptive use by men during the treatment period, and for at least 49 weeks after the last administration of IMP (BIVV020 + SOC arm participant) or last treatment period visit (SOC arm participant).\n\nExclusion Criteria:\n\n* Participants who are ABO incompatible with their donors.\n* Participants with known active ongoing infection as per below:\n\n  1. Positive HIV.\n  2. Positive HBV.\n  3. HCV with detectable HCV RNA.\n  4. Within 4 weeks of first study intervention: any serious infection, or any active bacterial infection, or any other infection which is clinically significant in the option of the Investigator, unless it can be confirmed that infection was cleared at least 3 days prior to first study intervention.\n* History of active tuberculosis (TB) regardless of treatment.\n* Participants with clinical diagnosis of systemic lupus erythematosus (SLE).\n* Prior treatment with complement system inhibitor within 5 times the half-life.\n* Current enrollment in any other clinical study where the last investigational study treatment administration was within 5 half-lives from study intervention initiation.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Trial Transparency email recommended (Toll free number for US & Canada)",
                    "role": "CONTACT",
                    "phone": "800-633-1610",
                    "phoneExt": "option 6",
                    "email": "Contact-US@sanofi.com"
                }
            ],
            "locations": [
                {
                    "facility": "Cedars-Sinai Medical Center Site Number : 8400100",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California Los Angeles (UCLA) - Ronald Reagan UCLA Medical Center Site Number : 8400103",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California San Francisco Site Number : 8400001",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Massachusetts General Hospital Site Number : 8400007",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Brigham & Women's Hospital Site Number : 8400004",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "NYU Langone Medical Center Site Number : 8400102",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University Of Wisconsin Hospital And Clinics Site Number : 8400003",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53792",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240101",
                    "status": "RECRUITING",
                    "city": "Vancouver",
                    "state": "British Columbia",
                    "zip": "V5Z 1M9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 49.24966,
                        "lon": -123.11934
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240001",
                    "status": "RECRUITING",
                    "city": "Vancouver",
                    "state": "British Columbia",
                    "zip": "V6Z 1Y6",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 49.24966,
                        "lon": -123.11934
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240002",
                    "status": "RECRUITING",
                    "city": "London",
                    "state": "Ontario",
                    "zip": "N6A 5A5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 42.98339,
                        "lon": -81.23304
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240003",
                    "status": "RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H4A 3J1",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Investigational Site Number : 2500007",
                    "status": "RECRUITING",
                    "city": "Bordeaux",
                    "zip": "33000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 44.84044,
                        "lon": -0.5805
                    }
                },
                {
                    "facility": "Investigational Site Number : 2500002",
                    "status": "RECRUITING",
                    "city": "Creteil",
                    "zip": "94000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.78333,
                        "lon": 2.46667
                    }
                },
                {
                    "facility": "Investigational Site Number : 2500001",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75010",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Investigational Site Number : 2500005",
                    "status": "RECRUITING",
                    "city": "Toulouse",
                    "zip": "31059",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.60426,
                        "lon": 1.44367
                    }
                },
                {
                    "facility": "Investigational Site Number : 2760002",
                    "status": "RECRUITING",
                    "city": "Berlin",
                    "zip": "13353",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 52.52437,
                        "lon": 13.41053
                    }
                },
                {
                    "facility": "Investigational Site Number : 2760004",
                    "status": "RECRUITING",
                    "city": "Essen",
                    "zip": "45122",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.45657,
                        "lon": 7.01228
                    }
                },
                {
                    "facility": "Investigational Site Number : 2760001",
                    "status": "RECRUITING",
                    "city": "M\u00fcnchen",
                    "zip": "81675",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 48.13743,
                        "lon": 11.57549
                    }
                },
                {
                    "facility": "Investigational Site Number : 3800004",
                    "status": "RECRUITING",
                    "city": "Bologna",
                    "state": "Emilia-Romagna",
                    "zip": "40138",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.49381,
                        "lon": 11.33875
                    }
                },
                {
                    "facility": "Investigational Site Number : 3800002",
                    "status": "RECRUITING",
                    "city": "Roma",
                    "state": "Lazio",
                    "zip": "00168",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "Investigational Site Number : 3800001",
                    "status": "RECRUITING",
                    "city": "Brescia",
                    "state": "Lombardia",
                    "zip": "25123",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.53558,
                        "lon": 10.21472
                    }
                },
                {
                    "facility": "Investigational Site Number : 3800003",
                    "status": "RECRUITING",
                    "city": "Milano",
                    "zip": "20126",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Investigational Site Number : 7240004",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "state": "Barcelona [Barcelona]",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Investigational Site Number : 7240001",
                    "status": "RECRUITING",
                    "city": "Madrid / Madrid",
                    "state": "Madrid, Comunidad De",
                    "zip": "28007",
                    "country": "Spain"
                },
                {
                    "facility": "Investigational Site Number : 7240003",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "state": "Madrid, Comunidad De",
                    "zip": "28041",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Investigational Site Number : 7240002",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "state": "Madrid, Comunidad De",
                    "zip": "28046",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Investigational Site Number : 7520001",
                    "status": "RECRUITING",
                    "city": "Huddinge",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 59.23705,
                        "lon": 17.98192
                    }
                },
                {
                    "facility": "Investigational Site Number : 7520002",
                    "status": "RECRUITING",
                    "city": "Uppsala",
                    "zip": "751 85",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 59.85882,
                        "lon": 17.63889
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "35332298",
                    "type": "DERIVED",
                    "citation": "Karpman D, Bekassy Z, Grunenwald A, Roumenina LT. A role for complement blockade in kidney transplantation. Cell Mol Immunol. 2022 Jul;19(7):755-757. doi: 10.1038/s41423-022-00854-5. Epub 2022 Mar 24. No abstract available."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "ACT17012 kidney transplant - antibody-mediated rejection website",
                    "url": "http://www.sanofistudies.com/O9BR/"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "removedCountries": [
                "Australia"
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069283",
                    "term": "Rituximab"
                },
                {
                    "id": "D000016559",
                    "term": "Tacrolimus"
                },
                {
                    "id": "D000007136",
                    "term": "Immunoglobulins"
                },
                {
                    "id": "D000016756",
                    "term": "Immunoglobulins, Intravenous"
                },
                {
                    "id": "D000000906",
                    "term": "Antibodies"
                },
                {
                    "id": "D000000961",
                    "term": "Antilymphocyte Serum"
                },
                {
                    "id": "D000005719",
                    "term": "gamma-Globulins"
                },
                {
                    "id": "D000018029",
                    "term": "Rho(D) Immune Globulin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000065095",
                    "term": "Calcineurin Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "asFound": "Eligible",
                    "relevance": "HIGH"
                },
                {
                    "id": "M373",
                    "name": "Rituximab",
                    "asFound": "Infusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "asFound": "Eligible",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12128",
                    "name": "Mycophenolic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M18950",
                    "name": "Tacrolimus",
                    "asFound": "Term",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19117",
                    "name": "Immunoglobulins, Intravenous",
                    "asFound": "Cannulation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8836",
                    "name": "gamma-Globulins",
                    "asFound": "Cannulation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20191",
                    "name": "Rho(D) Immune Globulin",
                    "asFound": "Cannulation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4279",
                    "name": "Antilymphocyte Serum",
                    "asFound": "Velcade",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M30452",
                    "name": "Calcineurin Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}